乙型肝炎病毒相关慢加急性肝衰竭诊断标准与预后评分的建立
该前瞻性研究基于中国13家肝病中心1322例慢性乙型肝炎急性失代偿或严重肝损伤住院患者,提出不论有无肝硬化,总胆红素≥12 mg/dL且INR≥1.5应诊断为慢加急性肝衰竭,新标准使19.3%的乙型肝炎病因患者额外获得诊断,并建立优于其他五种评分的短期死亡预后评分。
要点
- 不论有无肝硬化,慢性乙型肝炎患者总胆红素≥12 mg/dL且INR≥1.5应诊断为慢加急性肝衰竭。
- 新诊断标准使19.3%的乙型肝炎病因患者额外诊断为慢加急性肝衰竭。
- 新预后评分(0.741×INR+0.523×HBV-SOFA+0.026×年龄+0.003×总胆红素)在发现集和外部验证中均优于其他五种评分。
核心结论
- 不论是否存在肝硬化,慢性乙型肝炎患者总胆红素≥12 mg/dL且INR≥1.5应诊断为慢加急性肝衰竭。
- 新标准使近20%更多的乙型肝炎病因患者诊断为慢加急性肝衰竭,从而增加其及时接受强化管理的机会。
研究设计与样本
- 前瞻性研究,纳入中国13家肝病中心1322例因肝硬化急性失代偿或慢性乙型肝炎所致严重肝损伤的住院患者,用于建立新的诊断和预后标准。
主要发现
- 采用慢性肝衰竭联盟标准(排除肝硬化)评估,共识别391例慢加急性肝衰竭患者:92例非肝硬化乙型肝炎病毒相关慢加急性肝衰竭、271例肝硬化乙型肝炎病毒相关慢加急性肝衰竭、28例非乙型肝炎病因所致肝硬化慢加急性肝衰竭。
- 乙型肝炎病毒相关慢加急性肝衰竭患者的短期(28/90天)死亡率显著高于非乙型肝炎病毒相关慢加急性肝衰竭患者。
- 总胆红素≥12 mg/dL且INR≥1.5被提出作为乙型肝炎病毒相关慢加急性肝衰竭的额外诊断指标,19.3%的乙型肝炎病因患者被额外诊断为慢加急性肝衰竭。
- 新预后评分(0.741×INR+0.523×HBV-SOFA+0.026×年龄+0.003×总胆红素)在发现集和外部验证研究中均优于其他五种评分。
关键数值与推荐
- 乙型肝炎病毒相关慢加急性肝衰竭的额外诊断指标:总胆红素≥12 mg/dL且INR≥1.5。
- 新预后评分公式:0.741×INR+0.523×HBV-SOFA+0.026×年龄+0.003×总胆红素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The definition of acute-on-chronic liver failure (ACLF) based on cirrhosis, irrespective of aetiology, remains controversial. This study aimed to clarify the clinicopathological characteristics of patients with hepatitis B virus-related ACLF (HBV-ACLF) in a prospective study and develop new diagnostic criteria and a prognostic score for such patients. DESIGN: The clinical data from 1322 hospitalised patients with acute decompensation of cirrhosis or severe liver injury due to chronic hepatitis B (CHB) at 13 liver centres in China were used to develop new diagnostic and prognostic criteria. RESULTS: Of the patients assessed using the Chronic Liver Failure Consortium criteria with the exception of cirrhosis, 391 patients with ACLF were identified: 92 with non-cirrhotic HBV-ACLF, 271 with cirrhotic HBV-ACLF and 28 with ACLF with cirrhosis caused by non-HBV aetiologies (non-HBV-ACLF). The short-term (28/90 days) mortality of the patients with HBV-ACLF were significantly higher than those of the patients with non-HBV-ACLF. Total bilirubin (TB) ≥12 mg/dL and an international normalised ratio (INR) ≥1.5 was proposed as an additional diagnostic indicator of HBV-ACLF, and 19.3% of patients with an HBV aetiology were additionally diagnosed with ACLF. The new prognostic score (0.741×INR+0.523×HBV-SOFA+0.026×age+0.003×TB) for short-term mortality was superior to five other scores based on both discovery and external validation studies. CONCLUSIONS: Regardless of the presence of cirrhosis, patients with CHB, TB ≥12 mg/dL and INR ≥1.5 should be diagnosed with ACLF. The new criteria diagnosed nearly 20% more patients with an HBV aetiology with ACLF, thus increasing their opportunity to receive timely intensive management.
引用
- Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. 2017. PMID: 28928275. doi:10.1136/gutjnl-2017-314641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。